Up-regulated glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is observed in multiple cancers with unclear mechanism. Using GAPDH transgenic mouse and a mouse model of diethylnitrosamine-induced hepatocellular carcinoma (HCC), here we show that GAPDH overexpression aggravated tumor development by activating cell proliferation and inflammation. In cultured hepatic cells, overexpression of GAPDH or a catalytic domain-deleted GAPDH (GAPDH DCD ) affected metabolism, up-regulated phosphoglycerate dehydrogenase (PHGDH), increased histone methylation levels, and promoted proliferation. Consistently, inhibition of GAPDH by short hairpin RNA reprogrammed metabolism downregulated PHGDH and histone methylation, and inhibited proliferation. The xenograft study suggested that HepG2 cells overexpressing GAPDH or GAPDH DCD similarly promoted tumor development, whereas knockdown PHGDH in GAPDH overexpressing cells significantly inhibited tumor development. In liver sections of HCC patients, increased GAPDH staining was found to be positively correlated with PHGDH and histone methylation staining. Conclusion: GAPDH increases histone methylation levels by up-regulating PHGDH, promoting diversion from glycolysis to serine biosynthesis, and consequently accelerating HCC development. (HEPATOLOGY 2017;66:631-645).
H epatocellular carcinoma (HCC) is the most common liver cancer. The development and progression of HCC are influenced by multiple factors, including genetics and epigenetics. (1) Because cancer cells require extra energy and metabolites to sustain abnormal proliferation, it is important to understand metabolic reprogramming in cancer cells. Glycolysis boost is observed in many cancer cells. (2) Using the National Institutes of Health database dbEST for gene expression and ESTs, overexpression of glycolysis-related genes has been found in a set of 24 cancers, including HCC. (3) Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is a well-known housekeeping protein, which consists of an N-terminal NAD 1 binding domain and a Cterminal catalytic domain (Supporting Fig. S1 ). Using NAD 1 as a cofactor, the active tetrameric form of GAPDH converts glyceraldehyde-3-phosphate into glycerate-1,3-bisphosphate, and the latter is rapidly converted to 3-phosphoglycerate and generates ATP. (4) Abbreviations: CSF1, colony-stimulating factor 1; CT, control empty vector; DEN, diethylnitrosamine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GAPDH DCD , catalytic domain-deleted GAPDH; GAPDH shPHGDH , GAPDH plus shPHGDH; GAPDH shScram , GAPDH plus shScram; HCC, hepatocellular carcinoma; mRNA, messenger RNA; PHGDH, phosphoglycerate dehydrogenase; qPCR, quantitative real-time polymerase chain reaction; shRNA, short hairpin RNA; Tg, transgenic; WT, wild-type.
This key reaction links glycolysis, serine biosynthesis, and glycerol biosynthesis. (4) In addition to its important role in metabolism, GAPDH is also involved in DNA repair, cell death, autophagy, and apoptosis, depending on its cellular location and posttranslational modifications. (5) Moreover, a study that used Northern blotting to analyze the tumors from eight HCC patients reported elevated GAPDH messenger RNA (mRNA), (6) whereas down-regulation of GAPDH by antiglycolytic agents or short hairpin RNA (shRNA) has been reported to have anti-cell proliferation effects in colorectal cancer cells and lung cancer cells. (7, 8) However, whether and how GAPDH regulates tumorigenesis, especially in HCC, remains unclear.
Serine, an essential precursor for bio-macromolecules such as phosphatidylserine and sphingosine, is critical for cancer cell growth because serine-glycine metabolism refuels the one carbon cycle (comprising the methionine cycle and the folate cycle), which is responsible for cellular methylation and biosynthesis of many macromolecules. (9) (10) (11) Homocysteine can be recycled into methionine, which delivers the methyl group to S-adenosylmethionine, the major cellular methyl donor, which supports methylation of bio-macromolecules such as DNA and histones. (12) Altered histone methylation levels have been reported to associate with tumor initiation and progression. (13) De novo serine biosynthesis starts from conversion of 3-phosphoglycerate, a GAPDH-mediated reaction product, into 3-phosphohydroxypyruvate, which is catalyzed by phosphoglycerate dehydrogenase (PHGDH), the ratelimiting enzyme of serine synthesis. (11) Consistent with the excessive need of serine in cancer cells, PHGDH has been recently found up-regulated in breast, (9) colon (14) and lung (15) cancers, which makes PHGDH a putative oncogene.
Here, we found GAPDH promotes hepatic cell proliferation and tumor growth independent of its glycolytic activity. GAPDH affects methionine metabolism and histone methylation levels by regulating PHGDH, which plays a critical role in GAPDHinduced acceleration of tumorigenesis. Therefore, GAPDH accelerates HCC development via promoting diversion from glycolysis to serine biosynthesis.
Materials and Methods

MICE
GAPDH transgenic (Tg) mice in C57BL/6J background were generated, bred, and genotyped as reported previously. (16) Male BALB/c nude mice were purchased from Hunan SJA Laboratory Animal. Animals were handled according to the Guidelines of China Animal Welfare Legislation and approved by the Committee on Ethics in the Care and Use of Laboratory Animals of College of Life Sciences, Wuhan University.
TUMOR INDUCTION AND TISSUE COLLECTION
Male mice were intraperitoneally injected with diethylnitrosamine (DEN), a hepatic procarcinogen (25 mg/kg body weight; Sigma, St. Louis, MO), or phosphate-buffered saline at 2 weeks old and were sacrificed at 36 weeks old. Tumors with a diameter greater than 3 mm were measured individually and counted. Serum was collected for GAPDH activity and homocysteine measurements.
MICROARRAY DATA ANALYSIS
Livers from 6-month-old wild-type (WT, n 5 5) and GAPDH Tg (n 5 3) male mice were collected; RNA was extracted individually and pooled for microarray analysis as reported previously. (17) Additional details are provided in the Supporting Information.
HISTOLOGICAL AND IMMUNOHISTOLOGICAL ANALYSIS
For immunohistochemical staining, sections were processed as reported previously (18) and were incubated overnight with the respective primary antibodies (additional details are provided in the Supporting Information). Positive staining was visualized by reacting with DAB substrate (Vector Laboratories, Burlingame, CA), and sections were costained with hematoxylin.
CELL CULTURE, PLASMIDS, AND TRANSFECTION
The human HCC cell line HepG2, an immortalized human hepatocyte cell line L02, and a large T antigen transformed human embryonic kidney cell line 293T were used. Plasmid information is provided in the Supporting Information. Transfection was performed using FuGENE HD (Promega, Madison, WI) following the manufacturer's instructions.
PLATE COLONY FORMATION AND SOFT AGAR COLONY ASSAY
For plate colony formation, 2000 cells of different groups were plated in 6-well plates. For soft agar colony assay, 1000 cells were plated in soft agar in 12-well plates. Additional details are provided in the Supporting Information. 6 cells for each group were injected subcutaneously into the flanks of 6-week-old BALB/c nude mice. Tumor volume was measured and calculated as reported previously. (19) For BIX01294 treatment, 10 days after the nude mice developed GAPDH-or control empty vector (CT)-induced tumors, BIX01294 (Targetmol, Boston, MA) was injected either subcutaneously at 25 mg/kg each frank or intraperitoneally at 50 mg/kg, once a day for 3 days. Mice were sacrificed 20 days after cell injection, and the tumors were dissected and weighted.
TUMOR XENOGRAFT
MTT ASSAY
MTT assay was performed as described previously (20) ; additional details are provided in the Supporting Information. The absorbance measured at 490 nm was normalized to the respective control group, which was arbitrarily set as one.
ANALYSIS OF CELL METABOLITES
Cellular metabolites from L02 cells and livers of different groups were extracted and analyzed by way of gas chromatography-mass spectrometry or highperformance liquid chromatography, with details provided in the Supporting Information. Serum homocysteine was measured using an ELISA kit (Nanjing Jiancheng Bioengineering, China) following the manufacturer's instructions.
WESTERN BLOTS
Freshly isolated livers or cultured cells were sonicated in ice-cold RIPA buffer (Beyotime, China) and protein concentrations were determined. Western blots were performed as we previously reported (21) with antibody information provided in Supporting Table S1 .
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Extraction of total RNA, complementary DNA synthesis and quantitative real-time polymerase chain reaction (qPCR) assays were performed as described previously. (22) Actb or Rn18s were used as the internal controls. Primers used are provided in Supporting  Table S2 .
Chromatin Immunoprecipitation
HepG2 cells were cross-linked using 1% formaldehyde and stopped by adding 0.125 M glycine. The chromatin immunoprecipitation assay was performed as described previously. (23) Chromatin was immunoprecipitated with an anti-GAPDH antibody (sc-25778; Santa Cruz Biotechnology, Dallas, TX) and purified. The enrichment of immunoprecipitated DNA and inputs were detected by qPCR. Primer sequences are provided in Supporting Table S2 . The input samples were used as the internal control.
Co-immunoprecipitation
Protein (500 lg) was precleaned with mouse IgG (sc-2025, Santa Cruz Biotechnology) with protein G/A agarose (GE Healthcare, Chicago, IL), then subjected to immunoprecipitation by an anti-Flag antibody (AG729, Beyotime, China) with protein G/A agarose. The immune complexes were collected, washed, and subjected to immunoblotting.
STATISTICAL ANALYSIS
All results are expressed as the mean 6 standard error of the mean. All the cell experiments were repeated for three times. Data was analyzed using the nonparametric Kruskal-Wallis test followed by the Mann-Whitney test for comparison of more than two groups, whereas the Mann-Whitney test was used for two-group comparison. A t test was used in liver metabolite analysis. Linear regression analysis was performed using GraphPad Prism V5.0. Differences were considered statistically significant at P < 0.05.
Results
GAPDH ACTIVATES CELL PROLIFERATION IN MOUSE LIVER
The mRNA and/or protein levels of GAPDH were significantly increased in the liver, muscle, kidney and heart in GAPDH Tg mice (Supporting Figs. S2A,B and S3). Consistently, the GAPDH activity in the serum of Tg mice was 1.5-fold of that of WT mice (Supporting Fig. S2C ). Because GAPDH is involved in glycolysis and gluconeogenesis, we detected the transcription levels of five rate-limiting enzymes associated with glucose metabolism in livers of WT and GAPDH Tg mice. No significant difference in the mRNA levels of enzymes involved in glycolysis (phosphofructokinasePfk and pyruvate kinase-Pk), gluconeogenesis (phosphoenolpyruvate carboxykinase-Pck), and pentose phosphate pathway (glucose-6-phosphate dehydrogenase-G6pd) was found (Supporting Fig. S2D ). Similarly, there was no difference in liver protein levels of pyruvate kinase (liver and RBC type), phosphofructokinase (liver type), and phosphoenolpyruvate carboxykinase 1 between two groups (Supporting Fig. S2E ,F).
To identify altered genes in the livers of GAPDH Tg mice, microarray analysis was performed. Gene Ontology analysis suggested overexpression of GAPDH in the liver is strongly associated with up-regulation of cell cyclerelated genes (Fig. 1A) . Consistently, several key cell cycle regulating proteins, including cyclin D1, CDK4, and CDK6, were up-regulated in the livers of Tg mice (Fig.  1B) . Moreover, CDK6 was up-regulated in muscle, kidney and heart, whereas cyclin D1 was up-regulated in muscle in GAPDH Tg mice (Supporting Fig. S3 ).
GAPDH OVEREXPRESSION EXACERBATES TUMOR DEVELOPMENT IN MOUSE LIVER
Because activated cell cycle may accelerate tumorigenesis, (24) we studied whether overexpression of GAPDH promotes hepatic tumor development in mouse. A schematic workflow of generation of DEN-induced HCC is illustrated ( Fig. 1C) . At 34-week after DEN injection, physiological parameters were similar between WT and Tg mice, with or without DEN injection (Supporting Table S3 ). DEN successfully induced HCC in WT and Tg mice (Fig. 1D) , with a significantly greater number of tumors and larger tumor size found in Tg mice (Fig.  1E,F) . In contrast, no spontaneous tumor or other pathological change was found in the livers of mice without DEN treatment (Fig. 1D ,E).
GAPDH OVEREXPRESSION ENHANCES CELL PROLIFERATION AND INFLAMMATION, ESPECIALLY UPON DEN INDUCTION
Proliferation is a fundamental characteristic of cancer cells. (25) Ki67, a well-known cell proliferation marker, (26) was stained to detect proliferation state. In liver sections of WT and Tg mice, a dramatically increased number of proliferating cells were found after DEN induction; notably, the number of proliferating cells in Tg mouse was 10-fold of that of WT mice after DEN challenge ( Fig. 2A) . Almost no positive staining was found in livers without DEN induction ( Fig. 2A) . Under enhanced staining condition, increased Ki67 staining was observed in livers of Tg mice compared to that of WT mice without DEN-induction (Supporting Fig. S4 ).
Inflammation and immune evasion are also hallmarks of cancer progression. (27) As expected, after DEN induction, the number of macrophages (identified with F4/80 1 staining) in the livers of WT and Tg mice was increased, and the number of macrophages of Tg mice was 2-fold that of WT mice (Fig. 2B) . Consistently, overexpression of GAPDH increased the transcription levels of inflammatory factors such as Il6, Il1b, Mcp1, Icam1, and Vcam1 in DEN-injured livers (Fig. 2C ). This inflammation aggravation was further verified by observation of significantly up-regulated p-STAT3 Ser727 and p-STAT3 Tyr705 , two major activated forms of STAT3, a transcription factor known activated after being stimulated by cytokines, (28) in livers of Tg mice compared with those of WT upon DEN induction (Fig. 2D) . These results suggested an escalating role of GAPDH in HCC development by promoting cell proliferation and exacerbating cancerrelated inflammation.
GAPDH AND GAPDH
DCD
PROMOTE CELL PROLIFERATION
To investigate how GAPDH regulates tumor progression and whether the catalytic activity of GAPDH is required for the regulation of cell proliferation and development of HCC, a human full-length GAPDH (GAPDH) and catalytic domain-deleted GAPDH (GAPDH DCD ) plasmids (both Flag-tagged) were constructed. The mRNA and/or protein level of GAPDH (indicated by the Flag level) were up-regulated at a similar level in L02 cells (Fig. 3A,B) after being transiently transfected with GAPDH or GAPDH DCD . Native polyacrylamide gel electrophoresis results suggested that GAPDH can exist as dimers and tetramers (the latter has glycolytic activity (4) ) in L02 cells transfected with the empty vector (CT, Supporting Fig. S5A ). Overexpression of GAPDH or GAPDH DCD enhanced dimer formation, whereas GAPDH but not GAPDH DCD enhanced tetramer formation (Supporting Fig. S5A ). Consistently, whereas GAPDH DCD overexpressing cells showed similar GAPDH activity as that of CT cells, the GAPDH activity of GAPDH overexpressing cells was 1.5-fold higher (Supporting Fig. S5B) .
Surprisingly, GAPDH or GAPDH DCD overexpression both promoted cell proliferation in L02 cells at a similar level (Fig. 3C) . Usually, malignant tumors can adapt, survive and proliferate in hypoxia conditions caused by uncontrolled proliferation. (29) We found that GAPDH or GAPDH DCD overexpression both enhanced cell proliferation at a similar level under hypoxia conditions in L02 cells (Fig. 3D) . Similar overexpression efficacy of GAPDH/GAPDH DCD and their effects on cell proliferation were also observed in HepG2 cells (Supporting Fig. S5C-E) . To investigate the effect of GAPDH or GAPDH DCD overexpression on tumor growth, subcutaneous xenograft experiments were performed. Compared with nude mice injected with CT cells, significantly increased tumor growth rate and tumor size/weight were found in mice injected with HepG2 cells stably overexpressing GAPDH or GAPDH DCD during the experimental period (Fig.  3E) . Notably, there was no difference in tumor growth rate and tumor size/weight between the GAPDHand GAPDH DCD -induced xenografts (Fig. 3E,F) . Together, these results suggest a catalytic-independent yet NAD 1 binding domain-dependent role of GAPDH in tumorigenesis. Because the function of GAPDH is associated with its cellular location, (5) we traced the cellular location of GAPDH using GFP tag. In L02 cells, endogenous GAPDH was mostly enriched in cytoplasm in a diffused manner (Supporting Fig. S5F ), whereas overexpression of GAPDH induced its nuclear translocation and aggregation (dot-like structure) in cytoplasm; in contrast, GAPDH DCD overexpression induced a similar level of nuclear translocation of GAPDH but a much lower level of cytoplasmic aggregation (Supporting Fig. S5G ). Similar results were also obtained in HepG2 cells (Supporting Fig. S5G ).
GAPDH KNOCKDOWN INHIBITS CELL PROLIFERATION IN CULTURED HEPATIC CELLS
To further investigate the effects of GAPDH on cell proliferation, shRNA was used to knock down GAPDH in L02 and HepG2 cells. Good knockdown efficacy was achieved by shGAP-1 and shGAP-2, two GAPDH targeting shRNAs, in L02 cells (Fig. 4A,B ) and HepG2 cells (Supporting Fig. S6A-B) . Consistent with the overexpression results, GAPDH knockdown significantly inhibited cell proliferation in both cell lines as demonstrated by MTT assay (Fig. 4C and Supporting Fig. S6C ), plate colony formation (Supporting Fig. S6D ), and soft agar colony assays ( Fig.  4D and Supporting Fig. S6E ).
GAPDH REGULATES METHIONINE CYCLE AND HISTONE METHYLATION IN CULTURED HEPATIC CELLS AND IN LIVER
Cell metabolites from L02 cells overexpressing GAPDH or GAPDH DCD were analyzed by metabolomic approaches using gas chromatography-mass spectrometry or high-performance liquid chromatography. Multivariate analysis was applied to investigate the comparison among cells overexpressing CT, GAPDH,
FIG. 3. GAPDH promotes cell proliferation and affects cellular metabolites independent of its glycolytic activity. (A,B) Representative results of GAPDH overexpression efficiency at mRNA level (A, n 5 4) and protein level (B). (C,D) Cell viability of L02 cells determined by MTT analysis after overexpressing the control vector (CT), GAPDH, or GAPDH DCD in normal (C) or 4 hours hypoxia (1% O 2 ) (D). (E,F) Tumor growth rate (E) and tumor weight at the sacrifice day (F) of xenograft induced by HepG2 cells overexpressing CT, GAPDH, or GAPDH
DCD , treated with or without 50 mg/kg/day BIX01294. (CT 5 8; GAPDH 5 8; GAPDH DCD 5 7; CT 1 BIX s.c 5 8; GAPDH 1 BIX s.c 5 8;). ns, not significant. Data represent three independent experiments. *P < 0.05 versus CT or GAPDH-GFP-overexpressed cells.
or GAPDH
DCD
. The principal components analysis and supervised analysis by orthogonal partial least squares discriminant analysis elucidated the discrimination among three groups (Fig. 5A, top panel) . Notably, methionine and putrescine (a metabolite from the salvage pathway of methionine synthesis) were significantly up-regulated in both GAPDH and GAPDH DCD overexpression cells compared with CT cells (Fig. 5B) . Metabolomic analysis was also performed in the shScram and shGAP-1 cells (Fig. 5A, bottom panel) , which consistently identified that down-regulation of putrescine and cysteine, a methionine cycle metabolite, was responsible for separating shGAP-1 cells from shScram cells (Fig. 5B ). Similar conclusion was drawn when comparing shScram with shGAP-2 cells (data not shown). These results indicated that dysregulated methionine cycle may contribute to GAPDH-induced cellular metabolism reprogramming. Compared with untreated WT or Tg mice, upon DEN induction, significantly increased levels of serine was observed in livers of GAPDH Tg mice but not WT mice (Supporting Fig. S7A ), suggesting that the livers of Tg mice are prone to synthesize more serine upon DEN stimulation. Compared with untreated mice, the levels of methionine were significantly higher in livers of DENinjured WT or Tg mice (Supporting Fig. S7B ). Moreover, among DEN-injured mice, significantly higher methionine level in livers of GAPDH Tg mice was observed compared with that of WT mice. Furthermore, increased serum homocysteine level was found in DENinjured mice; for mice without DEN challenge, significantly increased serum homocysteine level was found in GAPDH Tg mice compared with WT mice (Supporting Fig. S7C ). Together, these results suggest an altered one-carbon cycle in GAPDH Tg mice and upon DEN induction.
Methionine metabolism is a major component of one-carbon metabolism, which supplies most of the cellular methyl groups. Because dysregulated methionine metabolism was observed in vitro and in vivo, we hypothesized that GAPDH may affect protein methylation levels. Significantly decreased lysine methylation (MeK) levels, which mainly occurred at 17 kD (the molecular weight of histone H3), was observed in GAPDH knockdown cells (Fig. 5C ). Among the nine histone lysine methylation sites we investigated, H3K9me2, H3K9me3, and H3K27me2 were significantly down-regulated in GAPDH knockdown L02 (Fig. 5D ) and HepG2 cells (Supporting Fig. S6F ). Other sites, including H3K4me3, H3K36me3, H3K79me1, and H4K20me3, were unchanged, whereas H3K27me3 and H3K36me1 were downregulated in shGAP-1 cells but not shGAP-2 cells (data not shown). On the other hand, H3K9me2, H3K9me3, and H3K27me3 were up-regulated in L02 cells overexpressing either GAPDH or GAPDH DCD (Fig. 5E) . Consistently, compared with WT mice, elevated levels of H3K9me2 and H3K9me3 in livers of Tg mice were observed with or without DEN induction ( Fig. 5F and Supporting Fig. S7D ).
To identify responsible histone methyltransferase or demethylase for observed changes on histone methylations, the expression levels of G9a, GLP, Suv39H1, and UTX were examined. Compared with WT mice, only Suv39H1, an H3K9 methyltransferase, was significantly up-regulated in the livers of Tg mice upon DEN induction (Supporting Fig. S8A ) and without DEN induction (data not shown); while in cultured L02 cells, knockdown of GAPDH down-regulated both Suv39H1 and G9a (Supporting Fig. S8B ).
To test whether altered histone methylation levels affect cell proliferation, an H3K9 methylation inhibitor BIX01294, was used. Dose-dependent inhibition of cell proliferation was observed after BIX01294 treatment in L02 and HepG2 cells transiently transfected with vector or GAPDH (Supporting Fig. S9 ). Furthermore, dramatic inhibition of GAPDH-induced and vector-induced tumor xenografts by either subcutaneous (Fig. 3E,F) or intraperitoneal injection (data not shown) of BIX01294 were found. Together, these results suggest that GAPDH regulates cellular metabolism and histone methylation, which promote cell proliferation.
GAPDH REGULATES PHGDH
We next investigated why altered GAPDH levels lead to changes of methionine cycle and histone methylation levels. Serine biosynthesis pathway was examined, not only because it is a branch pathway in glucose conversion, (11) but also due to the critical role of serine-glycine metabolism that links the folate cycle and the methionine cycle by refueling one-carbon units. (12) We found PHGDH, the key enzyme of serine biosynthesis, was down-regulated in shGAP L02 cells (Fig. 6A,B) ; whereas overexpression of GAPDH normalized PHGDH level (Fig. 6A,B) . Chromatin immunoprecipitation results revealed that GAPDH binds to the promoter of PHGDH, and knockdown of GAPDH significantly decreased binding affinity (Fig.  6C) . Co-immunoprecipitation revealed that PHGDH binds to both GAPDH and GAPDH DCD (Fig. 6D) . In vivo study further demonstrated that PHGDH is up-regulated in livers of Tg mice at mRNA and protein levels upon DEN induction (Fig. 6E,F) .
PHGDH IS REQUIRED FOR GAPDH INDUCED TUMOR PROMOTION
The aforementioned results suggest that GAPDH influences histone methylation by regulating PHGDH. We constructed a stable PHGDH knockdown cell line in which no effect on GAPDH protein level but dramatically decreased cell proliferation rate were found (Fig. 7A,B) . Similar to knockdown of GAPDH, PHGDH knockdown also inhibited histone methylation levels (Fig. 7C) . We thus speculated that knockdown of PHGDH would inhibit the GAPDHinduced tumorigenesis. By injecting stable GAPDH sh-
Scram or GAPDH
shPHGDH HepG2 cells (verification data not shown) into the flanks of nude mice, we observed faster tumor growth (Fig. 7D) and larger tumor size in xenografts induced by GAPDH shScram cells compared with those induced by control cells (Fig. 7E) . Furthermore, xenografts induced by GAPDH shPHGDH cells showed significantly reduced tumor growth rate and tumor size (Fig. 7D-E ) compared with those induced by GAPDH shScram cells, demonstrating that PHGDH is required for GAPDH-induced tumor promotion.
GAPDH EXPRESSION IS ENHANCED IN HUMAN HCC AND CORRELATES WITH PHGDH AND H3 METHYLATIONS
Immumohistochemical staining of the sections of 55 HCC patients revealed that 65% (36 of 55 samples) of patients showed up-regulated GAPDH levels (Supporting Fig. S10A,D) , and the GAPDH expression level seemed correlate with the severity of HCC (Supporting Fig. S10B ). In the same set of sections, increased PHGDH was also observed (58%; 32 of 55 samples; Supporting Fig. S10C,D) . Linear regression analysis showed strong positive correlations between GAPDH and PHGDH in these HCC patients (Supporting Fig. S10E ). Co-localized GAPDH and PHGDH were observed by immunofluorescence staining in liver sections of HCC patients (Supporting Fig.  S10F ). Moreover, increased H3K9me3 and H3K27me2 were found in liver sections of HCC patients (Supporting Fig. S11A ), which were correlated with the level of GAPDH (P 5 0.0491 for H3K9me3/GAPDH; P 5 0.0015 for H3K27me2/ GAPDH; Supporting Fig. S11B,C) .
Similarly, significantly up-regulated mRNA and protein levels of GAPDH and PHGDH were also observed in human lung cancer compared with the adjacent lung tissue or nontumor lung tissue (from lung cystic diseases) (Supporting Fig. S12A,B) ; linear regression analysis suggested strong positive correlations between the mRNA and protein levels of GAPDH and PHGDH in these patients (Supporting Fig. S12C,D) .
Discussion
Compared with normal cells, tumor cells have altered metabolic and proliferation rates. Identifying differentially regulated metabolic pathways in cancer cells may provide clues for cancer therapy. In HCC, several metabolic pathways have been studied, including glycogen metabolism, glycolysis, pentose phosphate pathway and serine synthesis, (30) but how glycolytic enzyme GAPDH functions in HCC remains elusive. Here we demonstrate that GAPDH plays an enabling role in HCC development (Fig. 1) and report up-regulated GAPDH in HCC and lung cancer (Supporting Figs. S10 and S12). Overexpression of GAPDH increases the expression of cell cyclerelated factors and cell proliferation with or without DEN treatment (Fig. 1) . However, overexpression of GAPDH per se did not induce HCC in mice. Typically, HCCs have 20-100 mutations per genome, (31) and a single gene-induced cell proliferation usually cannot cause tumorigenesis. (32) Therefore, the hepatic procarcinogen DEN in combination with the GAPDH overexpression-induced cell proliferation may promote tumorigenesis in GAPDH Tg mice.
To our surprise, GAPDH and GAPDH
DCD
showed similar effects on cell proliferation under normoxia and hypoxia, a tumor microenvironment-simulating condition ( Fig. 3 and Supporting Fig. S5 ), and had a similar effect on tumor size in xenografts ( Fig.  3E-F) , suggesting that GAPDH may regulate HCC development independent of its catalytic activity. For currently available GAPDH inhibitors, 3-BrPA inhibits both enzyme activity and protein level of GAPDH, (33) whereas GAPDH segregator (GAPDS) prevents tetramer formation, which interrupts signaling pathways specifically regulated by the tetrameric GAPDH. (34) Therefore, the reported effects of these inhibitors on tumor development may be due to downregulated GAPDH level or disrupted GAPDH oligomerization. Our results also indicate the important role of the NAD 1 binding domain of GAPDH in tumorigenesis. The NAD 1 binding domain of GAPDH has been reported to bind to the 3 0 untranslated region of many mRNAs, including colony-stimulating factor 1 (CSF1), (35) a factor involves in cancer development, (36) thus maintaining the stability of CSF1 mRNA. Stabilizing the mRNA of oncogene such as CSF1 by the NAD 1 binding domain of GAPDH may be one of the reasons that GAPDH DCD promotes cell proliferation just like GAPDH. Furthermore, because NAD metabolism plays crucial roles in tumorigenesis, (37) we speculate that the NAD 1 binding domain of GAPDH may function as a sensor of cellular NAD 1 /NADH level, which eventually regulates certain tumorigenesisassociated signaling. However, all these possibilities await further investigation.
Cancer cells rely on aerobic glycolysis with high expression levels of glycolysis enzymes, accompanied by excessive generation of lactate, which is known as the Warburg effect. Consistently, many genes or proteins involved in glycolysis have been shown to regulate tumorigenesis. (38, 39) However, we found no significant difference in the levels of enzymes involved in glycolysis, gluconeogenesis, and pentose phosphate pathway in the livers of WT and Tg mice (Supporting Fig. S2 ), which may be due to fact that GAPDH is not a rate-limiting enzyme of glycolysis. The Warburg effect in cancer cells not only supplies energy (e.g., ATP produced by glycolysis) in a specific cancer cell environment such as hypoxia, it also-and perhaps more importantly-generates more intermediates to satisfy the metabolic demand of proliferating cells. (40) Moreover, the Warburg effect appears to be inconsistent across all tumors. (41) The observations that GAPDH DCD can regulate PHGDH, histone methylation, and cell proliferation just like GAPDH indicate that the role of GAPDH overexpression in HCC is more likely to regulate the generation of essential intermediates for tumor growth, but is unlikely to promote the glycolysis rate. We reasoned that as long as GAPDH and GAPDH DCD induce similar metabolic changes that affect cell proliferation, they shall have similar ability on tumor development, as we observed in vivo and in vitro.
We demonstrate that GAPDH and GAPDH DCD have a similar ratio of nuclear location and show similar effect on regulation of histone methylation levels (Supporting Fig. S5G and Fig. 5E ), which may explain their similar effects on cell proliferation. In fact, most of the glycolytic enzymes, including hexokinase, phosphofructokinase, phosphoglycerate kinase, and pyruvate kinase M2, have been found in the nucleus. (42) GAPDH has also been found in the nucleus, where it acts as a key component of the octamer binding protein-1 coactivator in S phase complex and binds to the promoter of histone H2B to initiate H2B transcription in S phase, thus participating in cell cycle regulation. (43) This study establishes that a glycolytic enzyme can regulate histone methylation level in mammalian cells independent of its catalytic function (Fig. 5E) , although a recent study has reported that a yeast glycolytic enzyme Pyk1 (homolog of pyruvate kinase M2) is involved in the synthesis of methyl donor that supplies H3K4 trimethylation. (44) However, how GAPDH/GAPDH DCD is translocated to the nuclei and whether this translocation requires PHGDH awaits further study. The metabolomics analysis demonstrated that GAPDH/GAPDH DCD regulates methionine metabolism, which is the center of the one-carbon cycle that supplies the methyl group for molecular methylation (Fig. 5) . Previously, GAPDH has been reported to control D-serine production in the hippocampus by interacting with serine racemase, which converts L-serine into Dserine, thereby influencing glutamatergic neurotransmission. (45) Serine metabolism is critical for cancer cells, and the diversion of glycolytic flux to serine metabolism contributes to tumor progression. (46) PHGDH, the gene encoding the key enzyme of serine biosynthesis, is transcriptionally activated by H3K9 methylation, which enhances cell proliferation and tumorigenesis in multiple cancer cell lines. (47) Thus, GAPDH may transcriptionally regulate PHGDH by modulating H3K9 methylation levels of promoters. Our results demonstrated that GAPDH affects the level of PHGDH in vivo and in vitro (Fig. 6 ), GAPDH may act as a transcription activator by binding to the promoter of PHGDH (Fig. 6 ), GAPDH and PHGDH both regulate histone methylation level in cultured hepatic cells (Figs. 5 and 7) . Increased GAPDH and PHGDH levels were further found in HCC and lung cancer patients with good correlation (Supporting Figs. S10 and S12); importantly, deficiency of PHGDH significantly inhibits GAPDH induced tumor growth in nude mice (Fig. 7) , indicating the effect of GAPDH on HCC is at least partly PHGDH-dependent. Thus, GAPDH and PHGDH play important roles in diversion of glycolytic flux into tumor growth-favored biosynthesis pathways.
Under diverse environmental stresses (e.g., DEN), GAPDH dysregulation affects its subcellular localization, leading to disrupted cell metabolism and cell cycle, making GAPDH a potential threat or target for cancer therapy. In conclusion, we demonstrate a nonglycolytic function of GAPDH that converts glycolysis flux into serine metabolism by increasing PHGDH and promotes histone methylation, which increases cell proliferation and accelerates liver tumorigenesis upon DEN induction (Fig. 7F) .
